“We intend to achieve both numbers before locking the database and having the readout because the primary endpoint is critical and the bleeding superiority test is also important. We remain on track for both and expect the readout in the first quarter of 2027.”

In context

“Cristian Massacesi (Chief Medical Officer and Head of Global Drug Development): Thank you, Akash. We need to accrue 430 events for the primary endpoint of stroke and systemic embolism and 530 events for the bleeding endpoint. We intend to achieve both numbers before locking the database and having the readout because the primary endpoint is critical and the bleeding superiority test is also important. We remain on track for both and expect the readout in the first quarter of 2027.”